Biogen Announces Positive CHMP Opinion For VUMERITY - Quick Facts

Biogen Inc. (BIIB) announced the Committee for Medicinal Products for Human Use has recommended granting marketing authorization for VUMERITY in the European Union. VUMERITY is a next-generation oral fumarate for the treatment of adults with relapsing-remitting multiple sclerosis.

The company said the positive CHMP opinion was based on data from pharmacokinetic bridging studies comparing VUMERITY and TECFIDERA. The CHMP also assessed findings from EVOLVE-MS-2, a large, multi-center phase 3 study.

VUMERITY is an oral fumarate with a distinct chemical structure from TECFIDERA, approved in the U.S. for the treatment of relapsing forms of multiple sclerosis in adults.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Merck & Co., Inc., known as MSD outside the U.S. and Canada, has recalled one lot of intravenous antibiotic Cubicin (daptomycin for injection) 500 mg for the potential presence of particulate matter identified as glass particles, the U.S. Food and Drug Administration or FDA said in a statement. The National Restaurant Association or NRA shot out a letter to the U.S. Conference of Mayors suggesting that expanded outdoor dining is the need of the hour for the restaurant industry to sustain the winter. The NRA also warned that thousands of restaurants without this facility could close down very soon. The U.S. Food and Drug Administration is investigating a multistate outbreak of Salmonella Oranienburg infections linked to whole, fresh onions. The outbreak has resulted in 652 illnesses in consumers across the U.S. to date. The traceback investigation has identified Hailey, Idaho -based ProSource Inc., also known as ProSource Produce, LLC, as a source.
Follow RTT